Notable Insider Filing: Jean Bienaime, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s insider Unloaded 139,487 Shares

November 23, 2016 - By Adrian Mccoy

Notable Insider Filing: Jean Bienaime, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s insider Unloaded 139,487 Shares

Jean Bienaime Insider Sell

As exposed in the D.C. based-SEC, a public form for the sale of 139,487 shares of Biomarin Pharmaceutical Inc by Jean Bienaime was filled. Jean Bienaime is at present the Chief Executive Officer of the Pinksheet-listed company. The legal report was filled on 23/11/2016. These shares were unloaded at average $86.6 per each share, and have a market value of $12,082,993 US Dollars, making the sale a considerable one. This is not her first insider trade, in the last month, she sold another 301,670 shares worth $25,121,474 USD. Because it was a significant transaction, it’s not likely to stay a secret one. Jean Bienaime currently owns 353,483 shares or 0.20% of Biomarin Pharmaceutical Inc’s market cap (share price times the number of shares outstanding).

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Out of 16 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 12 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 75% are positive. $175 is the highest target while $99 is the lowest. The $129.27 average target is 46.38% above today’s ($88.31) stock price. BioMarin Pharmaceutical has been the topic of 36 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Credit Suisse on Wednesday, January 20. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Conviction Buy” rating by Goldman Sachs on Monday, March 7. Oppenheimer maintained the shares of BMRN in a report on Tuesday, February 23 with “Perform” rating. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Cowen & Co on Tuesday, August 25. On Monday, November 7 the stock rating was downgraded by Piper Jaffray to “Neutral”. Wedbush maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Tuesday, January 19. Wedbush has “Neutral” rating and $117.0 price target. The rating was maintained by Piper Jaffray on Friday, August 5 with “Overweight”. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, March 22. The rating was initiated by Raymond James on Tuesday, September 1 with “Outperform”. The firm has “Overweight” rating given on Friday, February 26 by Barclays Capital.

Insitutional Activity: The institutional sentiment increased to 1.66 in 2016 Q2. Its up 0.38, from 1.28 in 2016Q1. The ratio increased, as 34 funds sold all BioMarin Pharmaceutical Inc. shares owned while 104 reduced positions. 37 funds bought stakes while 140 increased positions. They now own 153.99 million shares or 5.12% less from 162.30 million shares in 2016Q1.

Guggenheim Cap holds 150,467 shares or 0.04% of its portfolio. The France-based Bnp Paribas Invest Ptnrs has invested 0.1% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Tang Cap Mgmt Ltd Liability Corp has 90,215 shares for 3.13% of their US portfolio. Signaturefd Limited Liability last reported 86 shares in the company. Tiaa Cref Inv Mgmt Limited Liability Co accumulated 1.40M shares or 0.08% of the stock. Credit Suisse Ag last reported 550,633 shares in the company. Moreover, Aviva Public Ltd Co has 0.05% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 94,078 shares. Moreover, Commerzbank Aktiengesellschaft Fi has 0.09% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 177,243 shares. Kbc Nv last reported 0.05% of its portfolio in the stock. The Japan-based Tokio Marine Asset Management has invested 0.33% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Bank & Trust Of Ny Mellon Corporation holds 0.04% or 1.81M shares in its portfolio. Utah Retirement Sys has 0.06% invested in the company for 29,681 shares. Cqs Cayman Limited Partnership, a Cayman Islands-based fund reported 50,128 shares. Stifel has invested 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). The Maryland-based Calvert Invest has invested 0.04% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Insider Transactions: Since May 26, 2016, the stock had 0 insider buys, and 22 insider sales for $73.88 million net activity. Shares for $104,927 were sold by LAWLIS V BRYAN on Wednesday, July 27. 5,000 shares were sold by Davis George Eric, worth $452,100 on Friday, October 7. $146,992 worth of shares were sold by SPIEGELMAN DANIEL K on Monday, June 6. Shares for $28,700 were sold by Mueller Brian on Monday, August 1. Another trade for 41,666 shares valued at $3.86M was sold by BIENAIME JEAN JACQUES. $1.77 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was sold by Ajer Jeffrey Robert. FUCHS HENRY J also sold $1.32 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Thursday, May 26.

About 1.30 million shares traded hands. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 7.13% since April 21, 2016 and is downtrending. It has underperformed by 12.46% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for various diseases and medical conditions. The company has a market cap of $14.79 billion. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. It currently has negative earnings. The Company’s approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

According to Zacks Investment Research, “BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin’s lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.”

Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on February, 23. They expect $-0.40 earnings per share, up 31.03% or $0.18 from last year’s $-0.58 per share. After $-0.13 actual earnings per share reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts 207.69% negative EPS growth.

More news for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were recently published by: Nasdaq.com, which released: “Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $––.6 ..” on November 11, 2016. Nasdaq.com‘s article titled: “Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $9.8 million ..” and published on November 01, 2016 is yet another important article.

BMRN Company Profile

BioMarin Pharmaceutical Inc. (BioMarin), incorporated on October 25, 1996, develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. The Company’s approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and in other countries. Naglazyme received marketing approval in the United States, the European Union and in other countries. Kuvan was granted marketing approval in the United States and the European Union. Aldurazyme was approved for marketing in the United States, the European Union and in other countries. Firdapse received marketing approval in the European Union.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>